High Baseline Serum Uric Acid Linked to Increased Cardiovascular and Renal Risks in Type 2 Diabetes: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-12-13 03:30 GMT   |   Update On 2024-12-13 07:15 GMT

Brazil: A recent study conducted as part of the Rio de Janeiro Type 2 Diabetes Cohort has emphasized the significant role that baseline serum uric acid (sUA) levels and their subsequent changes play in predicting key health outcomes in individuals with type 2 diabetes (T2D).

The prospective cohort study, published in the Journal of Diabetes and its Complications, found that elevated baseline sUA levels were associated with a higher risk of cardiovascular events, renal complications, and peripheral neuropathy in patients with type 2 diabetes.

"Baseline sUA levels were linked to major adverse cardiovascular events (HR: 2.4), renal failure, and microalbuminuria, with women showing a stronger cardiovascular risk association (HR: 2.6) compared to men (HR: 1.2). Additionally, changes in sUA levels were specifically connected to an increased risk of renal failure (HR: 2.4)," the researchers reported.

Serum uric acid, a substance typically associated with gout and kidney disease, has been emerging as an important biomarker for complications in diabetes. Claudia R.L. Cardoso, Department of Internal Medicine, University Hospital Clementino Fraga Filho, School of Medicine; Universidade Federal do Rio de Janeiro, Brazil, and colleagues aimed to examine the relationships between baseline and changes in serum uric acid (sUA) levels and the risks of cardiovascular and microvascular outcomes, as well as mortality, in a type 2 diabetes cohort.

For this purpose, the researchers measured baseline serum uric acid (sUA) in 685 individuals, with 463 having a second sUA measurement during follow-up. The sUA was analyzed as a continuous variable and categorized into sex-specific tertile subgroups, along with low/high levels (>4.5 mg/dl for women; >5.5 mg/dl for men). Cox analyses were used to examine the risks associated with baseline sUA and its changes for all outcomes.

The study led to the following findings:

  • The median follow-up was 10.7 years, with 173 major cardiovascular events (MACEs), 268 all-cause deaths, 127 cases of microalbuminuria, 104 instances of renal failure, 160 cases of retinopathy, and 178 occurrences of peripheral neuropathy.
  • Baseline serum uric acid was a predictor for all outcomes except for all-cause mortality and retinopathy.
  • In tertile and high/low sUA analyses, hazard ratios (HRs) ranged from 1.6 (for microalbuminuria development) to 2.4 (for MACEs and cardiovascular mortality).
  • An interaction with sex was observed for MACEs, with an increased risk in women (HR: 2.6), but not in men (HR: 1.2).
  • Changes in sUA were linked to an increased risk of renal failure (HR: 2.4).

"In a prospective cohort, elevated baseline serum uric acid levels were associated with an increased risk of cardiovascular, renal, and peripheral neuropathy. However, changes in sUA were only linked to the risk of renal failure," the researchers concluded.

Reference:

Cardoso, C. R., Da Silva Pereira, L., Leite, N. C., & Salles, G. F. (2024). Prognostic importance of baseline and changes in serum uric acid for macro/microvascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort. Journal of Diabetes and its Complications, 39(1), 108921. https://doi.org/10.1016/j.jdiacomp.2024.108921


Tags:    
Article Source : Journal of Diabetes and its Complications

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News